| Field | Specification |
|---|---|
| UniProt # | |
| Applications | |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Assay time | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This ELISA kit applies to the in vitro quantitative determination of Human APLN concentrations in serum, plasma and other biological fluids.
Assay Principle
This ELISA kit uses the Competitive-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with Human APLN. During the reaction, Human APLN in the sample or standard competes with a fixed amount of Human APLN on the solid phase supporter for sites on the Biotinylated Detection Ab specific to Human APLN. Excess conjugate and unbound sample or standard are washed away, and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well and incubated. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns from blue to yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The concentration of Human APLN in tested samples can be calculated by comparing the OD of the samples to the standard curve.
Performance Specifications
| Sensitivity | 37.5 pg/mL |
|---|---|
| Detection Range | 62.5-4000 pg/mL |
| Total Assay Time | 2 h 30 min |
| Compatible Sample Types | Serum, plasma and other biological fluids |
| Species Reactivity | Human |
| Detection Method | Competitive |
| Precision (CV) | Both intra-CV and inter-CV are < 10%. |
| Recovery Rate | 80%-120% |
| Storage | 2-8℃,12 months |
✓ Research-Grade Validation
Specificity
This kit recognizes Human APLN in samples.No significant cross-reactivity or interference between Human APLN and analogues was observed
Safety & Regulatory
Handle reagents in accordance with institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for complete hazard and handling information. Contains components that may require special disposal procedures per local regulations.
This kit is validated for use with Serum, plasma and other biological fluids. For unlisted matrices (e.g., tissue lysate, urine), perform a spike-and-recovery experiment to confirm assay performance before generating reportable data. Sample dilution in the kit's provided diluent is recommended to minimize matrix interference.
The minimum detectable concentration (sensitivity) of this kit is 37.5 pg/mL. Values below this threshold should be reported as below the limit of detection (<LOD) and should not be extrapolated from the standard curve.
The total assay time from sample addition to absorbance reading is approximately 2 h 30 min, including all incubation, wash, and substrate steps. Hands-on time is typically 1–2 hours; most steps involve passive plate incubation. Plan the assay as a single uninterrupted session for best results.
Standard components of this Competitive ELISA Kit typically include: pre-coated microplate (96-well strip format), lyophilized or liquid recombinant APLN standard, detection antibody, streptavidin-HRP conjugate, TMB substrate, stop solution, wash buffer concentrate, and sample/standard diluent. Refer to the kit insert or datasheet for the exact component list and storage requirements.
This kit uses colorimetric (TMB/HRP) detection and requires a standard microplate absorbance reader capable of measuring at 450 nm. A reference wavelength of 570 nm or 630 nm is recommended to reduce background. No specialized fluorescence or luminescence reader is needed. Ensure the instrument is calibrated and the plate is clean and free of condensation before reading.
Tissue samples may contain endogenous or exogenous proteases during processing, leading to degradation of extracted proteins. Therefore, it's necessary to add protease inhibitors during processing to ensure the integrity of target proteins. If customers can keep samples cold and handle them quickly during processing, omitting the protease inhibitor may not have a significant effect. After preparation, samples should be tested promptly or immediately aliquoted and frozen at -20°C or -80°C.
What is the range of enzyme activity of your IL-2 freeze-dried powder
What is the principle of adding stop solution to stop color reaction in ELISA experiment?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Elabela Attenuates the TGF-β1-Induced Epithelial-Mesenchymal Transition of Peritoneal Mesothelial Cells in Patients Receiving Peritoneal Dialysis (2022) Frontiers in Pharmacology. 10.3389/fphar.2022.890881
The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure (2022) Biomedicines. 10.3390/biomedicines10071751
Discriminative Utility of Apelin-to-NT-Pro-Brain Natriuretic Peptide Ratio for Heart Failure with Preserved Ejection Fraction among Type 2 Diabetes Mellitus Patients (2022) Journal of Cardiovascular Development and Disease. 10.3390/jcdd9010023
Interplay between Myokine Profile and Glycemic Control in Type 2 Diabetes Mellitus Patients with Heart Failure (2022) Diagnostics. 10.3390/diagnostics12122940
Predictors of Kidney Function Outcomes and Their Relation to SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes Mellitus Who Had Chronic Heart Failure (2023) ADVANCES IN THERAPY. 10.1007/s12325-023-02683-y
Predictors for Irreversibility of Contrast-Induced Acute Kidney Injury in Patients with Obesity After Contrast-Enhanced Computed Tomography Coronary Angiography (2024) ADVANCES IN THERAPY. 10.1007/s12325-024-03036-z
Salivary Apelin and Asprosin Levels in Periodontitis and Diabetes Mellitus and Their Relationship with Clinical Periodontal Parameters (2026) Diagnostics. 10.3390/diagnostics16071054
Effect of Ramadan diurnal fasting on visceral adiposity and serum adipokines in overweight and obese individuals (2019) DIABETES RESEARCH AND CLINICAL PRACTICE. 10.1016/j.diabres.2019.05.023
Relationship between serum apelin, visfatin levels, and body composition in Polycystic Ovary Syndrome patients (2024) European Journal of Obstetrics & Gynecology and Reproductive Biology. 10.1016/j.ejogrb.2024.03.034
Myostatin Reduction Within the Myokine–Adipokine Network Predicts Aerobic Adaptation After High-Intensity Interval Training in Combat Athletes (2026) Applied Sciences-Basel. 10.3390/app16073161
Serum level of apelin-12 in acne patients: is it a marker of disease severity? (2025) ARCHIVES OF DERMATOLOGICAL RESEARCH. 10.1007/s00403-025-04375-9
Association of serum vaspin, apelin, and visfatin levels and stroke risk in a Chinese case-control study (2021) MEDICINE. 10.1097/MD.0000000000025184
The relationship of irisin, apelin-13, and immunological markers il-1α & amp, il-1β with diabetes in kidney failure patients (2025) CELLULAR AND MOLECULAR BIOLOGY. 10.14715/cmb/2024.70.12.15
Evaluation of Fibrosis Markers: Apelin and Transforming Growth Factor-β1 in Autosomal Dominant Polycystic Kidney Disease Patients (2016) THERAPEUTIC APHERESIS AND DIALYSIS. 10.1111/1744-9987.12412
Kynurenine–PARP-1 Link Mediated by MicroRNA 210 May Be Dysregulated in Pulmonary Hypertension (2022) Anatolian Journal of Cardiology. 10.5152/AnatolJCardiol.2021.861
Serum Apelin Levels and Ascending Aortic Aneurysm in Adults (2020) Indian Journal of Surgery. 10.1007/s12262-020-02440-3
Association of Apelin gene rs3115757 variation and expression with metabolic syndrome among female students in King Abdulaziz University (2021) Gene Reports. 10.1016/j.genrep.2021.101305
